Lugh@futurology.todayM to Futurology@futurology.todayEnglish · 12 days agoVerve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.investor.lilly.comexternal-linkmessage-square1linkfedilinkarrow-up19arrow-down10cross-posted to: [email protected]
arrow-up19arrow-down1external-linkVerve is developing a pipeline of gene editing medicines to address the drivers of atherosclerotic cardiovascular disease (ASCVD) through treatments that may only need to be given once in a lifetime.investor.lilly.comLugh@futurology.todayM to Futurology@futurology.todayEnglish · 12 days agomessage-square1linkfedilinkcross-posted to: [email protected]
minus-squareRiffraffintheroom [none/use name]@hexbear.netlinkfedilinkEnglisharrow-up1·12 days agoThat’s cool but I expect to never hear about this again ever.
